Table 2 Risk prediction of four potential biomarkers for PD patients in discovery and validation group
Biomarkers | Discovery | Validation | Combined-analysis | |||
|---|---|---|---|---|---|---|
OR (95% CI) | p value | OR (95% CI) | p value | OR (95% CI) | p value | |
CXCL12 | 9 (4.3–18.7) | 4.5 × 10–9 | 2.3 (1.1–4.6) | 0.02 | 3.8 (2.4–6.2) | 4.7 × 10–8 |
CX3CL1 | 3.1 (1.6–6.0) | 7.8 × 10–4 | 2.8 (1.4–5.4) | 2.4 × 10–3 | 2.9 (1.7–4.9) | 1.5 × 10–4 |
IL-8 | 19.0 (8.2–44.3) | 7.6 × 10–12 | 57.0 (18.5–174.7) | 1.9 × 10–12 | 26.9 (12.9–56.4) | 2.3 × 10–18 |
CCL15 | 0.3 (0.2–0.7) | 4.7 × 10–3 | 0.5 (0.2–1.0) | 0.045 | 0.4 (0.3–0.7) | 0.001 |